JP2014501717A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501717A5 JP2014501717A5 JP2013538883A JP2013538883A JP2014501717A5 JP 2014501717 A5 JP2014501717 A5 JP 2014501717A5 JP 2013538883 A JP2013538883 A JP 2013538883A JP 2013538883 A JP2013538883 A JP 2013538883A JP 2014501717 A5 JP2014501717 A5 JP 2014501717A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- triazol
- propan
- optionally substituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 201000010099 disease Diseases 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 210000003169 Central Nervous System Anatomy 0.000 claims 4
- 239000003098 androgen Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrugs Drugs 0.000 claims 3
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 claims 2
- DFHXGPAXOUDLRU-UHFFFAOYSA-N 1-(5,6-dichloroquinolin-2-yl)-2-methyl-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C=1C=C2C(Cl)=C(Cl)C=CC2=NC=1C(O)(C(C)C)C1=CNN=N1 DFHXGPAXOUDLRU-UHFFFAOYSA-N 0.000 claims 2
- MSVVIRWQIISUNJ-UHFFFAOYSA-N 1-(6,7-dichloroquinolin-2-yl)-2-methyl-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C=1C=C2C=C(Cl)C(Cl)=CC2=NC=1C(O)(C(C)C)C1=CNN=N1 MSVVIRWQIISUNJ-UHFFFAOYSA-N 0.000 claims 2
- MMVFJKFSRQHOKE-UHFFFAOYSA-N 1-(6,7-difluoroquinolin-2-yl)-2-methyl-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C=1C=C2C=C(F)C(F)=CC2=NC=1C(O)(C(C)C)C1=CNN=N1 MMVFJKFSRQHOKE-UHFFFAOYSA-N 0.000 claims 2
- FNQBQSDVRFAVIN-UHFFFAOYSA-N 1-(6,7-dimethoxyisoquinolin-3-yl)-2-methyl-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C1=C2C=C(OC)C(OC)=CC2=CN=C1C(O)(C(C)C)C1=CNN=N1 FNQBQSDVRFAVIN-UHFFFAOYSA-N 0.000 claims 2
- ZBZKIRAMMFHRIY-UHFFFAOYSA-N 1-(6,7-dimethoxynaphthalen-2-yl)-2-methyl-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C1=C2C=C(OC)C(OC)=CC2=CC=C1C(O)(C(C)C)C1=CNN=N1 ZBZKIRAMMFHRIY-UHFFFAOYSA-N 0.000 claims 2
- JLICWFKFYANSGY-UHFFFAOYSA-N 1-(6-cyclopropyloxyquinolin-2-yl)-2-methyl-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C=1C=C2C=C(OC3CC3)C=CC2=NC=1C(O)(C(C)C)C1=CNN=N1 JLICWFKFYANSGY-UHFFFAOYSA-N 0.000 claims 2
- IXJBYAKVAODCDH-UHFFFAOYSA-N 1-(6-methoxyquinolin-2-yl)-2-methyl-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C1=CC2=CC(OC)=CC=C2N=C1C(O)(C(C)C)C1=CNN=N1 IXJBYAKVAODCDH-UHFFFAOYSA-N 0.000 claims 2
- ZIHIZUXCVGENMF-UHFFFAOYSA-N 1-[5-chloro-6-(difluoromethoxy)quinolin-2-yl]-2-methyl-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C=1C=C2C(Cl)=C(OC(F)F)C=CC2=NC=1C(O)(C(C)C)C1=CNN=N1 ZIHIZUXCVGENMF-UHFFFAOYSA-N 0.000 claims 2
- AIUXFSOPHUPUAE-UHFFFAOYSA-N 1-[5-chloro-6-(trifluoromethoxy)quinolin-2-yl]-2-methyl-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C=1C=C2C(Cl)=C(OC(F)(F)F)C=CC2=NC=1C(O)(C(C)C)C1=CNN=N1 AIUXFSOPHUPUAE-UHFFFAOYSA-N 0.000 claims 2
- ZBRAJOQFSNYJMF-UHFFFAOYSA-N 1-[6,7-bis(difluoromethoxy)naphthalen-2-yl]-2-methyl-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C=1C=C2C=C(OC(F)F)C(OC(F)F)=CC2=CC=1C(O)(C(C)C)C1=CNN=N1 ZBRAJOQFSNYJMF-UHFFFAOYSA-N 0.000 claims 2
- KJTKVKVPHPNQSU-UHFFFAOYSA-N 1-[6,7-bis(difluoromethoxy)quinolin-2-yl]-2-methyl-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C=1C=C2C=C(OC(F)F)C(OC(F)F)=CC2=NC=1C(O)(C(C)C)C1=CNN=N1 KJTKVKVPHPNQSU-UHFFFAOYSA-N 0.000 claims 2
- DLIXONPOBWMUIO-UHFFFAOYSA-N 1-[6-(difluoromethoxy)naphthalen-2-yl]-2-methyl-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C=1C=C2C=C(OC(F)F)C=CC2=CC=1C(O)(C(C)C)C1=CNN=N1 DLIXONPOBWMUIO-UHFFFAOYSA-N 0.000 claims 2
- AXIPFQNHVNPUSH-UHFFFAOYSA-N 1-[6-chloro-5-(trifluoromethyl)quinolin-2-yl]-2-methyl-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C=1C=C2C(C(F)(F)F)=C(Cl)C=CC2=NC=1C(O)(C(C)C)C1=CNN=N1 AXIPFQNHVNPUSH-UHFFFAOYSA-N 0.000 claims 2
- KSQPNKNCQWCKRG-UHFFFAOYSA-N 1-[7-chloro-6-(trifluoromethyl)quinolin-2-yl]-2-methyl-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C=1C=C2C=C(C(F)(F)F)C(Cl)=CC2=NC=1C(O)(C(C)C)C1=CNN=N1 KSQPNKNCQWCKRG-UHFFFAOYSA-N 0.000 claims 2
- WUQFUZUYABSJAQ-UHFFFAOYSA-N 2-[1-hydroxy-2-methyl-1-(2H-triazol-4-yl)propyl]-5-(trifluoromethyl)quinoline-6-carbonitrile Chemical compound C=1C=C2C(C(F)(F)F)=C(C#N)C=CC2=NC=1C(O)(C(C)C)C1=CNN=N1 WUQFUZUYABSJAQ-UHFFFAOYSA-N 0.000 claims 2
- WLANGOHXOSKDPZ-UHFFFAOYSA-N 2-methyl-1-(2H-triazol-4-yl)-1-[6-(trifluoromethoxy)quinolin-2-yl]propan-1-ol Chemical compound C=1C=C2C=C(OC(F)(F)F)C=CC2=NC=1C(O)(C(C)C)C1=CNN=N1 WLANGOHXOSKDPZ-UHFFFAOYSA-N 0.000 claims 2
- YDAJLXIARQWZRW-UHFFFAOYSA-N 2-methyl-1-(6-methylsulfanylquinolin-2-yl)-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C1=CC2=CC(SC)=CC=C2N=C1C(O)(C(C)C)C1=CNN=N1 YDAJLXIARQWZRW-UHFFFAOYSA-N 0.000 claims 2
- MZRURODHGHUBKV-UHFFFAOYSA-N 2-methyl-1-[5-thiophen-2-yl-6-(2,2,2-trifluoroethoxy)quinolin-2-yl]-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C=1C=C2C(C=3SC=CC=3)=C(OCC(F)(F)F)C=CC2=NC=1C(O)(C(C)C)C1=CN=NN1 MZRURODHGHUBKV-UHFFFAOYSA-N 0.000 claims 2
- FPFLLZAGPFEDBQ-UHFFFAOYSA-N 2-methyl-1-[6-(1,3-oxazol-5-yl)naphthalen-2-yl]-1-(2H-triazol-4-yl)propan-1-ol Chemical compound C=1C=C2C=C(C=3OC=NC=3)C=CC2=CC=1C(O)(C(C)C)C1=CNN=N1 FPFLLZAGPFEDBQ-UHFFFAOYSA-N 0.000 claims 2
- -1 6- (Difluoromethoxy) -5- (thiophen-2-yl) quinolin-2-yl Chemical group 0.000 claims 2
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 2
- 208000008466 Metabolic Disease Diseases 0.000 claims 2
- 230000001780 adrenocortical Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000001419 dependent Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- LNCAMLLVHZJNDI-UHFFFAOYSA-N 2-methyl-1-(2H-triazol-4-yl)-1-[6-(2,2,2-trifluoroethoxy)naphthalen-2-yl]propan-1-ol Chemical compound C=1C=C2C=C(OCC(F)(F)F)C=CC2=CC=1C(O)(C(C)C)C1=CNN=N1 LNCAMLLVHZJNDI-UHFFFAOYSA-N 0.000 claims 1
- KTCVWHLVIFVXLY-UHFFFAOYSA-N 2-methyl-1-(2H-triazol-4-yl)-1-[6-(2,2,2-trifluoroethoxy)quinolin-2-yl]propan-1-ol Chemical compound C=1C=C2C=C(OCC(F)(F)F)C=CC2=NC=1C(O)(C(C)C)C1=CNN=N1 KTCVWHLVIFVXLY-UHFFFAOYSA-N 0.000 claims 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 claims 1
- 206010000496 Acne Diseases 0.000 claims 1
- 206010068168 Androgenetic alopecia Diseases 0.000 claims 1
- 206010002659 Anovulatory cycle Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010006232 Breast disease Diseases 0.000 claims 1
- 208000009745 Eye Disease Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims 1
- 206010020112 Hirsutism Diseases 0.000 claims 1
- 206010020718 Hyperplasia Diseases 0.000 claims 1
- 208000000509 Infertility Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 claims 1
- 208000010195 Onychomycosis Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000207 Urologic Disease Diseases 0.000 claims 1
- 206010046766 Uterine cancer Diseases 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 210000004291 Uterus Anatomy 0.000 claims 1
- 206010047486 Virilism Diseases 0.000 claims 1
- 230000001919 adrenal Effects 0.000 claims 1
- 239000003732 agents acting on the eye Substances 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 201000002996 androgenic alopecia Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 231100000552 anovulation Toxicity 0.000 claims 1
- 201000005670 anovulation Diseases 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001028 anti-proliferant Effects 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- YDVJBLJCSLVMSY-UHFFFAOYSA-N carbamoyl cyanide Chemical compound NC(=O)C#N YDVJBLJCSLVMSY-UHFFFAOYSA-N 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 201000010870 diseases of metabolism Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000009273 endometriosis Diseases 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 235000019000 fluorine Nutrition 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 230000002538 fungal Effects 0.000 claims 1
- 239000004083 gastrointestinal agent Substances 0.000 claims 1
- 201000002146 gastrointestinal system disease Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 201000010066 hyperandrogenism Diseases 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 231100000794 masculinization Toxicity 0.000 claims 1
- 201000004458 myoma Diseases 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 230000001568 sexual Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 201000007954 uterine fibroid Diseases 0.000 claims 1
- ROWUDZIYFDKEQM-UHFFFAOYSA-N C(Cc1ccccc1)CNc1cccc(-c2cnn[nH]2)c1 Chemical compound C(Cc1ccccc1)CNc1cccc(-c2cnn[nH]2)c1 ROWUDZIYFDKEQM-UHFFFAOYSA-N 0.000 description 1
- XWSXOJIGZDEFKO-UHFFFAOYSA-N C(c1c[o]cc1)Nc1cccc(-c2cnn[nH]2)c1 Chemical compound C(c1c[o]cc1)Nc1cccc(-c2cnn[nH]2)c1 XWSXOJIGZDEFKO-UHFFFAOYSA-N 0.000 description 1
- ICNTYHGHXVHTHC-UHFFFAOYSA-N C(c1ccccc1)Nc1cc(-c2cnn[nH]2)ccc1 Chemical compound C(c1ccccc1)Nc1cc(-c2cnn[nH]2)ccc1 ICNTYHGHXVHTHC-UHFFFAOYSA-N 0.000 description 1
- ATKJYZIOFWPDJD-UHFFFAOYSA-N C1Oc(c(-c2cnn[nH]2)ccc2)c2O1 Chemical compound C1Oc(c(-c2cnn[nH]2)ccc2)c2O1 ATKJYZIOFWPDJD-UHFFFAOYSA-N 0.000 description 1
- UQNMMYVQLOFKSL-UHFFFAOYSA-N C1Oc2cc(-c3cnn[nH]3)ccc2O1 Chemical compound C1Oc2cc(-c3cnn[nH]3)ccc2O1 UQNMMYVQLOFKSL-UHFFFAOYSA-N 0.000 description 1
- YHDCPALYQURDMR-UHFFFAOYSA-N C=[Br]c(cccc1)c1-c1cnn[nH]1 Chemical compound C=[Br]c(cccc1)c1-c1cnn[nH]1 YHDCPALYQURDMR-UHFFFAOYSA-N 0.000 description 1
- UKYMYESZZTWGIS-UHFFFAOYSA-N CC1C(CCNc2cccc(-c3cnn[nH]3)c2)=CC=CC1c1ccc(CNc2cccc(-c3cnn[nH]3)c2)[o]1 Chemical compound CC1C(CCNc2cccc(-c3cnn[nH]3)c2)=CC=CC1c1ccc(CNc2cccc(-c3cnn[nH]3)c2)[o]1 UKYMYESZZTWGIS-UHFFFAOYSA-N 0.000 description 1
- LPVPGKCWLFFGFF-UHFFFAOYSA-N COc(cc1)ccc1-c1cnn[nH]1 Chemical compound COc(cc1)ccc1-c1cnn[nH]1 LPVPGKCWLFFGFF-UHFFFAOYSA-N 0.000 description 1
- XQHCBHNLRWLGQS-UHFFFAOYSA-N Cc1cc(-c2cnn[nH]2)ccc1 Chemical compound Cc1cc(-c2cnn[nH]2)ccc1 XQHCBHNLRWLGQS-UHFFFAOYSA-N 0.000 description 1
- IYTHSSNIJXFAQN-UHFFFAOYSA-N Cc1cccnc1-c1cnn[nH]1 Chemical compound Cc1cccnc1-c1cnn[nH]1 IYTHSSNIJXFAQN-UHFFFAOYSA-N 0.000 description 1
- FYQBMGGHUIYNAG-UHFFFAOYSA-N Clc(cc1)ccc1Sc(cccc1)c1-c1cnn[nH]1 Chemical compound Clc(cc1)ccc1Sc(cccc1)c1-c1cnn[nH]1 FYQBMGGHUIYNAG-UHFFFAOYSA-N 0.000 description 1
- KYQRWVUQWNZHFU-UHFFFAOYSA-N Fc(cc1)ccc1-c1cnn[nH]1 Chemical compound Fc(cc1)ccc1-c1cnn[nH]1 KYQRWVUQWNZHFU-UHFFFAOYSA-N 0.000 description 1
- XQNLLPNGLMIYRT-UHFFFAOYSA-N Fc1ccccc1-c1cnn[nH]1 Chemical compound Fc1ccccc1-c1cnn[nH]1 XQNLLPNGLMIYRT-UHFFFAOYSA-N 0.000 description 1
- 0 I*(cc1)ccc1-c1cnn[n]1 Chemical compound I*(cc1)ccc1-c1cnn[n]1 0.000 description 1
- CONLIJVDXFCUGC-UHFFFAOYSA-N O=C(c1ccccc1)Nc1cccc(-c2cnn[nH]2)c1 Chemical compound O=C(c1ccccc1)Nc1cccc(-c2cnn[nH]2)c1 CONLIJVDXFCUGC-UHFFFAOYSA-N 0.000 description 1
- ZQTHEZHPRGQYNQ-UHFFFAOYSA-N OC1(CCCCC1)c1cnn[nH]1 Chemical compound OC1(CCCCC1)c1cnn[nH]1 ZQTHEZHPRGQYNQ-UHFFFAOYSA-N 0.000 description 1
- DCERZYFATQLVJN-UHFFFAOYSA-N c1c(-c2cnn[nH]2)[o]c2ccccc12 Chemical compound c1c(-c2cnn[nH]2)[o]c2ccccc12 DCERZYFATQLVJN-UHFFFAOYSA-N 0.000 description 1
Claims (23)
- 式(I)もしくは(II)の化合物、またはその塩、溶媒和物、水和物もしくはプロドラッグであり、
R3は、H、OH、アルコキシ、アミノ、アルキルアミノ、もしくはジアルキルアミノであり;
ここで化合物は、
式(I)もしくは(II)の化合物、またはその塩、溶媒和物、水和物もしくはプロドラッグ。 - R3がOHである、請求項1に記載の化合物。
- R2が任意選択的に置換されたアルキルであり、R3がOHである、請求項1に記載の化合物。
- R1が任意選択的に置換されたアリールであり、R2がアルキルであり、R3がOHである、請求項1に記載の化合物。
- R1が任意選択的に置換されたヘテロアリールであり、R2がアルキルであり、R3がOHである、請求項1に記載の化合物。
- R1が置換アリールであり、R2がアルキルであり、R3がOHである、請求項1に記載の化合物。
- R1が任意選択的に置換されたナフチルであり、R2がアルキルであり、R3がOHである、請求項1に記載の化合物。
- R1が置換ナフチルであり、R2がアルキルであり、R3がOHである、請求項7に記載の化合物。
- R1が、独立して、アルキル、アルコキシ、ハロアルコキシ、シアノ、ハロ、アミノ、モノ−アルキルアミノ、ジ−アルキルアミノ、またはヘテロアリールから選択される1、2、3または4置換基と置換されたナフチルである、請求項8に記載の化合物。
- XはCHであり、YはCHである、請求項10に記載の化合物。
- XはCHであり、YはNである、請求項10に記載の化合物。
- XはNであり、YはCHである、請求項10に記載の化合物。
- 以下:
1−(6,7−ジメトキシナフタレン−2−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(1);
1−(6,7−ジメトキシイソキノリン−3−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(2);
1−(6,7−ビス(ジフルオロメトキシ)ナフタレン−2−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(3);
2−メチル−1−(6−(オキサゾール−5−イル)ナフタレン−2−イル)−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(4);もしくは
1−(6,7−ジクロロキノリン−2−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(5);
1−(6−クロロ−5−(トリフルオロメチル)キノリン−2−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(6);
2−メチル−1−(6−(メチルチオ)キノリン−2−イル)−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(7);
1−(6−シクロプロポキシキノリン−2−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(8);
1−(7−クロロ−6−(トリフルオロメチル)キノリン−2−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(9);
1−(6−(ジフルオロメトキシ)−5−(チオフェン−2−イル)キノリン−2−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(10);
2−メチル−1−(5−(チオフェン−2−イル)−6−(2,2,2−トリフルオロエトキシ)キノリン−2−イル)−1−(1H−1,2,3−トリアゾール−5−イル)プロパン−1−オール(11);
2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)−1−(6−(2,2,2−トリフルオロエトキシ)ナフタレン−2−イル)プロパン−1−オール(12)
1−(6−(ジフルオロメトキシ)ナフタレン−2−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(13)
1−(6−メトキシキノリン−2−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(14)
2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)−1−(6−(2,2,2−トリフルオロエトキシ)キノリン−2−イル)プロパン−1−オール(15)
1−(6,7−ジフルオロキノリン−2−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(16)
2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)−1−(6−(トリフルオロメトキシ)キノリン−2−イル)プロパン−1−オール(17)
1−(5,6−ジクロロキノリン−2−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(18)
1−(5−クロロ−6−(ジフルオロメトキシ)キノリン−2−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(19)
1−(6,7−ビス(ジフルオロメトキシ)キノリン−2−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(20)
1−(5−クロロ−6−(トリフルオロメトキシ)キノリン−2−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(21)
1−(6−(4−フルオロフェニル)−5−(トリフルオロメチル)キノリン−2−イル)−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロパン−1−オール(22)
2−(1−ヒドロキシ−2−メチル−1−(1H−1,2,3−トリアゾール−4−イル)プロピル)−5−(トリフルオロメチル)キノリン−6−カルボニトリル(23);
またはその塩、溶媒和物、水和物もしくはプロドラッグである、請求項1に記載の化合物。 - 金属酵素活性を阻害するための薬品製造における使用のための、請求項1乃至請求項114の任意の一項に記載の化合物。
- 金属酵素関連障害または疾患を呈しているかまたはかかりやすい対象を治療するための薬品製造における使用のための、請求項1に記載の有効量の化合物。
- 前記疾患または障害が、癌、心血管疾患、炎症疾患、感染疾患、代謝疾患、眼疾患、中枢神経系(CNS)疾患、泌尿器疾患、または胃腸疾患である、請求項16に記載の化合物。
- 前記疾患または障害が、前立腺癌、乳癌、アンドロゲン依存性癌、エストロゲン依存性癌、副腎皮質過形成症、前立腺肥大、男性化、多毛、男性型脱毛症、性的早熟、子宮内膜症、子宮筋腫(uterus myoma)、子宮癌、乳腺症、多嚢胞性卵巣症候群、不妊症、座瘡、機能的アンドロゲン過剰、慢性無排卵を伴うアンドロゲン過剰、高アンドロゲン血症、早発性副腎皮質性思春期徴候、副腎もしくはアンドロゲン過剰、子宮筋腫(uterine fibroid)、炎症性腸疾患、乾癬、全身性真菌感染症、爪甲真菌症、または心血管疾患である、請求項16に記載の化合物。
- 請求項1に記載の化合物および農業的に許容される担体を含む組成物。
- 植物中または植物上の真菌増殖の治療または予防する薬品製造における使用のための、請求項1乃至14の任意の一項に記載の化合物。
- 請求項1に記載の化合物および薬学的に許容される担体を含む組成物。
- さらに、追加治療薬を含む、請求項21に記載の組成物。
- さらに、抗癌剤、抗真菌剤、心血管剤、抗炎症性剤、化学治療薬、抗血管形成剤、細胞障害性剤、抗増殖剤、代謝疾患剤、眼疾患剤、中枢神経系(CNS)疾患剤、泌尿器疾患剤、または胃腸疾患剤である追加治療薬を含む、請求項21に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41339510P | 2010-11-13 | 2010-11-13 | |
US61/413,395 | 2010-11-13 | ||
PCT/US2011/060166 WO2012064943A2 (en) | 2010-11-13 | 2011-11-10 | Metalloenzyme inhibitor compounds |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015199620A Division JP2016094390A (ja) | 2010-11-13 | 2015-10-07 | 金属酵素阻害化合物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014501717A JP2014501717A (ja) | 2014-01-23 |
JP2014501717A5 true JP2014501717A5 (ja) | 2014-05-15 |
JP5828343B2 JP5828343B2 (ja) | 2015-12-02 |
Family
ID=46051557
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013538883A Active JP5828343B2 (ja) | 2010-11-13 | 2011-11-10 | 金属酵素阻害化合物 |
JP2015199620A Pending JP2016094390A (ja) | 2010-11-13 | 2015-10-07 | 金属酵素阻害化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015199620A Pending JP2016094390A (ja) | 2010-11-13 | 2015-10-07 | 金属酵素阻害化合物 |
Country Status (13)
Country | Link |
---|---|
US (5) | US8389543B2 (ja) |
EP (2) | EP2638021B1 (ja) |
JP (2) | JP5828343B2 (ja) |
KR (2) | KR20180039185A (ja) |
CN (2) | CN106243051B (ja) |
AU (2) | AU2011326487B2 (ja) |
BR (1) | BR112013011830B1 (ja) |
CA (1) | CA2817691C (ja) |
EA (1) | EA024197B1 (ja) |
ES (1) | ES2703498T3 (ja) |
PT (1) | PT2638021T (ja) |
TW (1) | TWI600647B (ja) |
WO (1) | WO2012064943A2 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011285724B2 (en) | 2010-08-04 | 2015-01-22 | Pellficure Pharmaceuticals, Inc. | Combination therapy for the treatment of prostate carcinoma |
KR20180039185A (ko) * | 2010-11-13 | 2018-04-17 | 이노크린 파마슈티컬즈, 인크. | 금속효소 억제제 화합물 |
ES2774267T3 (es) * | 2012-01-20 | 2020-07-20 | Mycovia Pharmaceuticals Inc | Compuestos inhibidores de metaloenzimas |
CA2891412A1 (en) | 2012-11-20 | 2014-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
EP2968219B1 (en) * | 2013-03-14 | 2019-04-24 | Pellficure Pharmaceuticals, Inc. | Novel therapy for prostate carcinoma |
WO2015070366A1 (en) * | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
US9738613B2 (en) | 2015-05-18 | 2017-08-22 | National Central University | Substituted 1,2,3-triazoles as antitumor agents |
ES2970715T3 (es) | 2016-12-22 | 2024-05-30 | Prec Pharmaceuticals Inc | Composiciones y métodos para inhibir la actividad de la arginasa |
US11173145B2 (en) | 2017-01-17 | 2021-11-16 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
US20210292410A1 (en) * | 2017-12-07 | 2021-09-23 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
WO2019113312A1 (en) * | 2017-12-08 | 2019-06-13 | Innocrin Pharmaceuticals, Inc. | Anticancer compound process |
WO2019182743A1 (en) * | 2018-03-20 | 2019-09-26 | Innocrin Pharmaceuticals, Inc. | Compositions for the treatment of brain tumors |
WO2020018670A1 (en) | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
US20220370415A1 (en) * | 2018-10-11 | 2022-11-24 | Kembi Therapeutics Pty Ltd | Compositions for the treatment of brain tumors |
CN110256342B (zh) * | 2019-07-16 | 2022-06-07 | 河南省科学院化学研究所有限公司 | 一种2-氰基喹啉衍生物的合成方法 |
CN114957215B (zh) * | 2022-01-13 | 2023-03-21 | 渤海大学 | 亚甲基桥连喹啉和1,2,3-三唑双杂环化合物及其制备方法与应用 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
ATE107176T1 (de) | 1989-12-04 | 1994-07-15 | Searle & Co | System zur transdermalen albuterol applikation. |
US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
JPH07502219A (ja) | 1991-12-18 | 1995-03-09 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 多重層型バリアー構造体 |
EP0553769B1 (de) | 1992-01-29 | 1996-01-03 | FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG | Ballspielschläger, insbesondere Tennisschläger |
IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
CA2328973A1 (en) * | 1998-04-23 | 1999-10-28 | Akio Ojida | Naphthalene derivatives, their production and use |
US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
EP1274424A4 (en) * | 2000-04-12 | 2003-09-17 | Smithkline Beecham Corp | CONNECTIONS AND PROCEDURE |
JP2005508951A (ja) * | 2001-10-12 | 2005-04-07 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
PL375353A1 (en) * | 2002-08-22 | 2005-11-28 | Syngenta Participations Ag | Chemical compounds |
KR20060052799A (ko) * | 2003-07-10 | 2006-05-19 | 오에스아이 파마슈티컬스, 인코포레이티드 | 시토크롬 p450 억제제로서 나프틸렌 유도체 |
US7488745B2 (en) * | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
US7504424B2 (en) * | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
SI2430921T1 (en) * | 2007-04-03 | 2018-01-31 | E. I. Du Pont De Nemours And Company | Substituted benzene fungicides |
WO2008124703A2 (en) | 2007-04-05 | 2008-10-16 | Siemens Medical Solutions Usa, Inc. | Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry |
WO2009105140A2 (en) | 2007-12-11 | 2009-08-27 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
US20110118219A1 (en) * | 2008-03-25 | 2011-05-19 | University Of Maryland, Baltimore | Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
WO2010032874A1 (ja) | 2008-09-19 | 2010-03-25 | 住友化学株式会社 | 農業用組成物 |
CN102282133A (zh) * | 2008-10-28 | 2011-12-14 | 生物马林药物股份有限公司 | 十氢-1h-茚并喹啉酮和十氢-3h-环戊并菲啶酮cyp17抑制剂 |
WO2011088160A2 (en) * | 2010-01-15 | 2011-07-21 | Biomarin Pharmaceutical Inc. | Novel cyp17 inhibitors |
KR20180039185A (ko) * | 2010-11-13 | 2018-04-17 | 이노크린 파마슈티컬즈, 인크. | 금속효소 억제제 화합물 |
-
2011
- 2011-11-10 KR KR1020187009616A patent/KR20180039185A/ko not_active Application Discontinuation
- 2011-11-10 KR KR1020137015117A patent/KR101848077B1/ko active IP Right Grant
- 2011-11-10 US US13/293,891 patent/US8389543B2/en active Active
- 2011-11-10 JP JP2013538883A patent/JP5828343B2/ja active Active
- 2011-11-10 ES ES11839513T patent/ES2703498T3/es active Active
- 2011-11-10 AU AU2011326487A patent/AU2011326487B2/en active Active
- 2011-11-10 CN CN201610627095.9A patent/CN106243051B/zh not_active Expired - Fee Related
- 2011-11-10 WO PCT/US2011/060166 patent/WO2012064943A2/en active Application Filing
- 2011-11-10 CN CN201180064835.8A patent/CN103339115B/zh active Active
- 2011-11-10 BR BR112013011830-0A patent/BR112013011830B1/pt active IP Right Grant
- 2011-11-10 CA CA2817691A patent/CA2817691C/en active Active
- 2011-11-10 EA EA201390704A patent/EA024197B1/ru unknown
- 2011-11-10 PT PT11839513T patent/PT2638021T/pt unknown
- 2011-11-10 EP EP11839513.6A patent/EP2638021B1/en active Active
- 2011-11-10 EP EP18196254.9A patent/EP3483147A1/en not_active Withdrawn
- 2011-11-11 TW TW100141218A patent/TWI600647B/zh active
-
2013
- 2013-03-04 US US13/784,466 patent/US8623892B2/en active Active
-
2014
- 2014-01-06 US US14/148,318 patent/US20140121248A1/en not_active Abandoned
-
2015
- 2015-10-07 JP JP2015199620A patent/JP2016094390A/ja active Pending
-
2017
- 2017-02-02 US US15/423,235 patent/US20170143694A1/en not_active Abandoned
- 2017-06-01 AU AU2017203691A patent/AU2017203691A1/en not_active Abandoned
-
2018
- 2018-04-03 US US15/944,397 patent/US20180221364A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014501717A5 (ja) | ||
JP2014500864A5 (ja) | ||
JP2014517069A5 (ja) | ||
JP2014504287A5 (ja) | ||
JP2006504658A5 (ja) | ||
WO2009114994A1 (zh) | 哒嗪酮类化合物在制备抗肿瘤药物中的用途 | |
JP4607458B2 (ja) | 新規なアリールおよびへテロアリールピペラジン | |
AP1108A (en) | Farnesyl protein transferase inhibiting (imidazol-5-Y1) Methyl-2-Quinoline derivatives. | |
JP2016526535A5 (ja) | ||
JP2014525937A5 (ja) | ||
JP2015526487A5 (ja) | ||
JP2019502755A5 (ja) | ||
JP2013504523A5 (ja) | ||
JP2014520898A5 (ja) | ||
SK112893A3 (en) | Benzofuran derivatives, method of their preparation and pharmaceutical compositions containing them | |
JP2009534408A5 (ja) | ||
JP2013537203A5 (ja) | ||
JP2015172062A5 (ja) | ||
JP2017530962A5 (ja) | ||
CA2566544A1 (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
JP2016516699A5 (ja) | ||
JP2016512515A5 (ja) | ||
JP2008500992A5 (ja) | ||
CA2915054A1 (en) | Metalloenzyme inhibitor compounds | |
ES2260316T3 (es) | Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa. |